Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tonga Tech Press.
Press releases published on October 25, 2025
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing…
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolism Robust monotherapy activity, as well as combination activity with BBOT’s KRASG12C ON/OFF inhibitor, …
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating …
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of …
Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025
Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and inflammatory macrophages Broad mechanism of action of QEL- …
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consistent with …
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful increases in heartburn-free nights …
DeFi Crypto Mutuum Finance Completes Phase 1 Roadmap as V1 Protocol Launch Approaches
Dubai, UAE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- As the cryptocurrency market begins shifting its focus back to fundamentals, one new crypto project is standing out for its steady progress and structured delivery. Mutuum Finance (MUTM) has been methodically …
New Crypto Mutuum Finance (MUTM) Nears V1 Launch After Raising Over $17.8M
Dubai, UAE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- In a market where many blockchain projects promise innovation but struggle with execution, Mutuum Finance (MUTM) is quickly emerging as one of the top crypto demonstrating steady, measurable progress. The …
DebitMyData מספקת פתרון למשבר איסור היצוא העולמי של H20, חושפת את התפקיד הקריטי של Human Energy Grid
Human Energy Grid של DebitMyData פורט לודרדייל, פלורידה, Oct. 25, 2025 (GLOBE NEWSWIRE) -- DebitMyData™, Inc פרסמה עדכון חשוב עבור בעלי עניין גלובליים ולציבור הדיגיטלי בתגובה לאיסורי היצוא ובקרות הסחר האחרונות בהיבט של H20, המשפיעים על חדשנות בתחום הבינה …
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive …